Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients

Immune-related adverse events with PD-1/PD-L1 inhibitors: insights from a real-world cohort of 2523 patients

PurposeImmune checkpoint inhibitors (ICIs) have significantly changed cancer therapy, improving patient survival rates and clinical outcomes. Nevertheless, the use of PD-1/PD-L1 inhibitors can result in immune-related adverse events (irAEs). This study aims to investigate the prevalence and associat...

Full description

Saved in:
Bibliographic Details
Main Authors: Ting Yan, Minghui Long, Chaoyi Liu, Jiwen Zhang, Xingyu Wei, Fei Li, Dehua Liao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-01-01
Series:Frontiers in Pharmacology
Subjects:
PD-1/PD-L1 inhibitors
immune-related adverse events
real-world study
efficacy
tumor therapy
retrospective analysis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1519082/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1519082/full

Similar Items